

Revenue by quarter (DKKm)

Europe	FY 2005	Qtr1 06	Qtr2 06	H1 06	Qtr3 06	Qtr4 06	FY 2006	Qtr1 07	Qtr2 07	H1 07	Qtr3 07
Ciprallex®	1,963	600	643	1,243	643	675	2,561	673	706	1,379	728
Ebixa®	933	256	283	539	282	311	1,132	317	334	652	357
Azilect®	6	8	16	24	19	27	70	32	37	69	43
Serdolect®	-	1	2	3	1	3	7	7	4	12	6
Other pharmaceuticals *	1,777	364	353	716	324	313	1,353	304	281	586	274
Total revenue, Europe	4,680	1,228	1,296	2,525	1,269	1,329	5,123	1,334	1,364	2,697	1,408
US **	FY 2005	Qtr1 06	Qtr2 06	H1 06	Qtr3 06	Qtr4 06	FY 2006	Qtr1 07	Qtr2 07	H1 07	Qtr3 07
Income from Lexapro®	2,552	484	435	918	479	525	1,923	628	641	1,268	699
Other pharmaceuticals *	66	4	(5)	(1)	3	5	7	4	-	4	2
Total revenue, US	2,618	488	430	917	482	530	1,930	631	641	1,272	701
International Markets ***	FY 2005	Qtr1 06	Qtr2 06	H1 06	Qtr3 06	Qtr4 06	FY 2006	Qtr1 07	Qtr2 07	H1 07	Qtr3 07
Ciprallex®	662	237	213	450	235	262	948	317	321	638	318
Ebixa®	172	55	54	109	58	63	230	74	74	149	75
Azilect®	-	-	-	-	-	1	1	2	3	4	4
Serdolect®	-	-	-	-	1	1	3	2	2	4	5
Other pharmaceuticals *	706	168	147	315	149	149	613	157	150	307	168
Total revenue, International Markets	1,539	461	414	875	443	476	1,794	552	550	1,103	569
Other revenue	232	56	58	113	54	208	375	65	57	122	282
Total group revenue	9,070	2,232	2,198	4,431	2,248	2,543	9,221	2,583	2,612	5,194	2,960

* Incl. income from citalopram sales

** US (incl. income from Forest)

*** Asia, Australia, Africa, Americas, Canada, Middle East